Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with different psychiatric disorders
Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with different psychiatric disorders
复制标题
DOI：
10.1016/j.neulet.2010.10.003
复制
发表时间：
2011-01-03
影响因子：
2.5
通讯作者：
Politi, Pierluigi
中科院分区：
文献类型：
--
作者：
Emanuele, Enzo;Martinelli, Valentina;Politi, Pierluigi
有证据表明，精神病患者的血管风险增加。在这项探索性的初步研究中，我们假设晚期糖基化终末产物可溶性受体（sCRP）的低水平可能是由于其与动脉粥样硬化血栓形成的关系而在精神病患者中发现的。我们招募了74例不同精神疾病患者（39例精神分裂症，10例重度抑郁症，13例双相情感障碍和12例人格障碍）和74名健康对照。酶联免疫吸附试验测定血清sIgA水平。单因素分析显示，精神分裂症、抑郁症和双相情感障碍患者血清sIgA水平均显著低于对照组。这些诊断组的中位血清肌酐水平与既往有动脉粥样硬化血栓形成事件的患者报告的水平相当。在考虑了潜在的混杂因素后，severity降低的几率仍然与精神分裂症和重性抑郁症独立相关。尽管有待进一步证实，我们的研究结果表明，血清睾酮水平降低可能有助于增加精神分裂症和抑郁症患者的心血管风险。(C)2010爱思唯尔爱尔兰有限公司版权所有。
Evidence suggests that psychiatric patients are at an increased vascular risk. In this exploratory pilot study, we hypothesized that low levels of the soluble receptor for advanced glycation endproducts (sRAGE) might be found in psychiatric patients due to its association with atherothrombosis. We recruited 74 patients with different psychiatric disorders (39 schizophrenia, 10 major depression, 13 bipolar disorder and 12 personality disorder) and 74 healthy controls. Serum levels of sRAGE were determined by enzyme-linked immunosorbant assay. In univariate analysis, serum sRAGE levels of the patient groups with schizophrenia, major depression and bipolar disorder were significantly lower than that of the control group. The median sRAGE levels of these diagnostic groups were comparable with those reported in patients with prior atherothrombotic events. After allowance for potential confounders, the odds of reduced sRAGE remained independently associated with schizophrenia and major depression. Although subject to future confirmation, our findings suggest that the reduced serum sRAGE may contribute to increased cardiovascular risk in schizophrenia and major depression. (C) 2010 Elsevier Ireland Ltd. All rights reserved.